<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902002</url>
  </required_header>
  <id_info>
    <org_study_id>408-C-1804</org_study_id>
    <nct_id>NCT03902002</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function</brief_title>
  <official_title>A Single Dose, Open Label Pharmacokinetic Study of Omaveloxolone in Subjects With Mild, Moderate, or Severe Hepatic Impairment, or With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the pharmacokinetics (PK) of omaveloxolone following a single oral
      dose of omaveloxolone in subjects with mild, moderate, or severe hepatic impairment compared
      to healthy subjects with normal hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2019</start_date>
  <completion_date type="Actual">January 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of omaveloxolone in plasma</measure>
    <time_frame>15 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the the plasma omaveloxolone concentration-time curve (AUC)</measure>
    <time_frame>15 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Count of reported adverse events</measure>
    <time_frame>15 days</time_frame>
    <description>Safety and tolerability will be assessed by counting adverse events, as defined the Medical Dictionary for Regulatory Activities (MedDRA).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1: matched healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: subjects with mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: subjects with moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: subjects with severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone 50 mg capsules</intervention_name>
    <description>Capsules containing 50 mg of omaveloxolone</description>
    <arm_group_label>Group 1: matched healthy subjects</arm_group_label>
    <arm_group_label>Group 2: subjects with mild hepatic impairment</arm_group_label>
    <arm_group_label>Group 3: subjects with moderate hepatic impairment</arm_group_label>
    <arm_group_label>Group 4: subjects with severe hepatic impairment</arm_group_label>
    <other_name>RTA 408</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, of any race, between 18 and 70 years of age, inclusive.

          -  BMI between 18.0 and 38.0 kg/m2, inclusive, and body weight ≥ 50 kg.

          -  Females will not be pregnant (or planning to get pregnant) or lactating at Screening
             or Check in (Day 1), and females of childbearing potential and males will agree to use
             contraception .

          -  Male subjects must not donate sperm and female subjects must not donate ova from Check
             in (Day 1) until 90 days after their dose of study drug.

        Subjects with Normal Hepatic Function Only

          -  Matched to subjects with mild, moderate, or severe hepatic impairment in sex, age (±
             10 years), and BMI (± 20%).

          -  In good health, determined by no clinically significant findings from medical history,
             physical examination, 12 lead ECG, vital signs measurements, and clinical laboratory
             evaluations (congenital non hemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's
             syndrome based on total and direct bilirubin] is not acceptable) at Screening and
             Check in as assessed by the investigator (or designee).

        Subjects with Hepatic Impairment Only

          -  Documented chronic stable liver disease (Child Pugh Class A [mild], B [moderate], or C
             [severe] at Screening); diagnosis of cirrhosis due to parenchymal liver disease. This
             will exclude biliary liver cirrhosis or other causes of hepatic impairment not related
             to parenchymal disorder:

          -  'Documented' is defined by at least one of the following: medical history, physical
             examination, hepatic ultrasound, computed axial tomography scan, magnetic resonance
             imaging, and/or liver biopsy.

          -  'Chronic stable' is defined as no clinically significant change in disease status
             within the last 30 days, as documented by the subject's recent medical history (e.g.,
             no worsening of clinical signs of hepatic impairment, or no worsening of total
             bilirubin or prothrombin time [PT] by more than 50%).

          -  Subjects with mild, moderate, or severe hepatic impairment may have medical findings
             consistent with their hepatic dysfunction, as determined by medical history, physical
             examination, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations
             at Screening and Check in (Day 1). Subjects with abnormal findings considered not
             clinically significant by the investigator will be eligible.

        Exclusion Criteria:

          -  Significant history or clinical manifestation of any metabolic, allergic,
             dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal,
             neurological, respiratory, endocrine, or psychiatric disorder, as determined by the
             investigator (or designee).

          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance, unless approved by the investigator (or designee).

          -  History of stomach or intestinal surgery or resection that would potentially alter
             absorption and/or excretion of orally administered drugs (cholecystectomy will not be
             allowed; uncomplicated appendectomy and hernia repair will be allowed).

          -  Presence of any other condition (including surgery) known to interfere with the
             absorption, distribution, metabolism, or excretion of medicines.

          -  Ventricular dysfunction or history of risk factors for Torsade de Pointes (TdP; e.g.,
             unexplained syncope, known long QT syndrome, heart failure, and cardiomyopathy).
             Subjects will be excluded if there is a family history of long QT syndrome.

          -  Evidence of hepatorenal syndrome and estimated glomerular filtration rate (eGFR) ≤ 60
             mL/min/1.73 m2 or abnormal sodium and potassium levels, as determined by the
             investigator (or designee), calculated using the Chronic Kidney Disease Epidemiology
             Collaboration (CKD EPI) equation at Screening or Check in (Day 1).

          -  Clinically significant physical examination abnormality, as determined by the
             investigator (or designee).

          -  Use or intend to use any medications/products known to alter drug absorption,
             metabolism, or elimination processes, including St. John's wort, within 30 days prior
             to dosing, unless deemed acceptable by the investigator (or designee).

          -  Use of any sensitive substrates for cytochrome P450 (CYP)2C8, moderate or strong
             inhibitors or inducers of CYP3A4/5, or substrates for p glycoprotein (P gp) within 30
             days prior to study drug administration.

          -  Consumption of grapefruit, grapefruit products, star fruit, star fruit products, or
             Seville oranges within 72 hours prior to study drug administration (Day 1) and
             throughout the study (until after the Follow up Visit).

          -  History of alcoholism or drug/chemical abuse within 6 months prior to Check in (Day
             1).

          -  Alcohol consumption of &gt; 21 units per week for males and &gt; 14 units for females. One
             unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL)
             wine within the 6 months prior to Check in (Day 1).

          -  Positive urine drug screen or positive alcohol breath or urine test result at
             Screening and Check in (Day 1), that is not otherwise explained by permitted
             concomitant medications. A positive alcohol test may be repeated once at Screening. A
             positive alcohol test may not be repeated at Check in (Day 1).

          -  Positive human immunodeficiency virus test (Appendix 2).

          -  Participation in a clinical study involving administration of an investigational drug
             (new chemical entity) in the past 30 days or 10 half lives (if known), whichever is
             longer, prior to dosing.

          -  Current enrollment in another clinical study.

          -  Receipt of blood products within 2 months prior to Check in.

          -  Donation or loss of ≥ 550 mL blood from 3 months prior to Screening, plasma from 2
             weeks prior to Screening, or platelets from 6 weeks prior to Screening.

        Subjects with Normal Hepatic Function Only

          -  Confirmed supine blood pressure &gt; 140 mmHg or &lt; 90 mmHg and/or supine diastolic blood
             pressure &gt; 90 mmHg or &lt; 50 mmHg, or resting (supine) heart rate &lt; 45 beats per minute
             (bpm) or &gt; 100 bpm at Screening or Check in (Day 1), with a QT interval corrected for
             heart rate using Fridericia's method (QTcF) &gt; 450 ms for male subjects and &gt; 470 ms
             for female subjects.

          -  Positive hepatitis panel (Appendix 2).

          -  Use of tobacco or nicotine containing products within 6 months prior to Check in (Day
             1), or positive cotinine at Screening or Check in (Day 1).

          -  Clinically significant abnormal laboratory values (clinical chemistry, hematology,
             coagulation, and urinalysis), as determined by the investigator (or designee).

          -  Significant history or clinical manifestation of hepatic disorder, as determined by
             the investigator (or designee).

          -  History or presence of liver disease or liver injury as indicated by any clinically
             significant deviations from normal reference ranges in liver function tests, unless
             approved by the investigator (or designee).

          -  History of diabetes mellitus.

          -  Use or intend to use any prescription medications/products other than prescribed
             hormone replacement therapy, implantable, or intrauterine contraceptives within 30
             days prior to dosing, unless deemed acceptable by the investigator (or designee).

          -  Use or intend to use slow release medications/products considered to still be active
             within 30 days prior to Check in (Day 1), unless deemed acceptable by the investigator
             (or designee).

          -  Use or intend to use any non prescription medications/products including vitamins,
             minerals, and phytotherapeutic , herbal , or plant derived preparations within 7 days
             prior to Check in (Day 1), unless deemed acceptable by the investigator (or designee).

        Subjects with Hepatic Impairment Only

          -  Confirmed supine blood pressure &gt; 150 mmHg or &lt; 90 mmHg and/or supine diastolic blood
             pressure &gt; 90 mmHg or &lt; 50 mmHg, or resting (supine) heart rate &lt; 45 bpm or &gt; 100 bpm
             at Screening or Check in (Day 1), with a QTcF &gt; 470 ms for both male and female
             subjects.

          -  History of clinically significant left sided heart disease and/or clinically
             significant cardiac disease.

          -  Values outside the normal range for liver function tests that are not consistent with
             their hepatic condition, as determined by the investigator (or designee).

          -  Use of a new medication, or a change in dose, for the treatment of hepatic
             encephalopathy within 90 days prior to Check in (Day 1).

          -  Use of prescription drugs within 30 days prior to Check in (Day 1), with the exception
             of therapies for hepatic disease and treatment of associated disorders that had been
             stable for at least 3 months prior to administration of study drug (Day 1) or
             prescribed hormone replacement therapy, implantable, or intrauterine contraceptives.

          -  Recent history of, or the treatment of, esophageal bleeding (within the past 180
             days), unless banded.

          -  History of unstable diabetes mellitus (as evidenced by hemoglobin A1c [HbA1c] ≥ 9.0%
             at Screening). Concomitant medications for the treatment of diabetes mellitus must be
             approved by the investigator (or designee), Sponsor, and Covance Medical Monitor.

          -  Presence of a portosystemic shunt.

          -  Recent history of paracentesis within 90 days prior to Check in (Day 1).

          -  Current functioning organ transplant or awaiting an organ transplant.

          -  Evidence of severe ascites.

          -  Recent history of hepatic encephalopathy (Grade 2 or above) within 180 days prior to
             Screening.

          -  Smoke more than 10 cigarettes or use the equivalent tobacco or nicotine containing
             products per day or inability to refrain from tobacco use 2 hours pre dose until 4
             hours post dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RTA 408</keyword>
  <keyword>RTA 408 capsules</keyword>
  <keyword>Omaveloxolone</keyword>
  <keyword>Omaveloxolone capsules</keyword>
  <keyword>Hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

